Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Anixa Biosciences, Inc. ANIX
$3.54
-$0.14 (-4.07%)
На 18:01, 12 мая 2023
+125.99%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
119370114.00000000
-
week52high
6.45
-
week52low
2.77
-
Revenue
2469000000
-
P/E TTM
-10
-
Beta
0.95363300
-
EPS
-0.39000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 июн 2022 г. в 20:00
Описание компании
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 12 апр 2021 г. | |
| Aegis Capital | Buy | 23 мар 2020 г. | |
| B. Riley | Buy | Buy | 30 дек 2019 г. |
| Chardan Capital | Buy | 23 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Gottschalk Emily | A | 25000 | 25000 | 03 янв 2023 г. |
| KUMAR AMIT | A | 700000 | 700000 | 03 янв 2023 г. |
| Baskies Arnold M | A | 25000 | 25000 | 03 янв 2023 г. |
| Titterton Lewis H jr | A | 25000 | 25000 | 03 янв 2023 г. |
| Catelani Michael | A | 350000 | 350000 | 03 янв 2023 г. |
| Catelani Michael | A | 20290 | 1069 | 31 окт 2022 г. |
| Titterton Lewis H jr | D | 0 | 40000 | 29 сент 2022 г. |
| Titterton Lewis H jr | A | 774070 | 40000 | 29 сент 2022 г. |
| KUMAR AMIT | D | 0 | 640000 | 15 сент 2022 г. |
| KUMAR AMIT | D | 462100 | 491900 | 15 сент 2022 г. |
Новостная лента
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
25 апр 2023 г. в 11:32
Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Seeking Alpha
18 апр 2023 г. в 19:13
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data
Zacks Investment Research
18 апр 2023 г. в 12:55
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"
Zacks Investment Research
28 окт 2022 г. в 10:32
ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PRNewsWire
31 авг 2022 г. в 08:30
SAN JOSE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C.